E1

inactivated Factor IXa] in a sufficient amount over a sufficient time period to inhibit coagulation so as to thereby treat the ischemic disorder in the subject, wherein the antagonist is selected from the group consisting of a peptide mimetic, a nucleic acid, a small molecule, a carbohydrate molecule, and an antibody.--

E2

--49.(amended) The method of claim 46, wherein the pharmaceutically acceptable form comprises [chemically inactivated Factor IXa and] a pharmaceutically acceptable carrier.--

--50.(amended) The method of claim 49, wherein the carrier comprises an [aerosol,] intravenous [, oral or topical] carrier.--

Please introduce new claims 56-66 as follows:

E3

--56.(new) The method of claim 46, wherein the antagonist interferes with Factor IXa binding.--

--57.(new) The method of claim 46, wherein the antagonist interferes with Factor IXa binding to epithelium or to platelets.--

--58.(new) The method of claim 46, wherein the antagonist is a peptide mimetic.--

--59.(new) The method of claim 46, wherein the antagonist is a nucleic acid.--